Senecavirus A as an Oncolytic Virus: Prospects, Challenges and Development Directions

Oncolytic viruses have the capacity to selectively kill infected tumor cells and trigger protective immunity. As such, oncolytic virotherapy has become a promising immunotherapy strategy against cancer. A variety of viruses from different families have been proven to have oncolytic potential. Seneca...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 12; p. 839536
Main Authors Luo, Dankun, Wang, Haiwei, Wang, Qiang, Liang, Wenping, Liu, Bo, Xue, Dongbo, Yang, Yang, Ma, Biao
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 17.03.2022
Subjects
cancer
combination therapy
immunotherapy
Oncology
oncolytic virus
senecavirus A
virotherapy
combination therapy
cancer
senecavirus A
virotherapy
oncolytic virus
immunotherapy
Online AccessGet full text

Cover

More Information
Summary:Oncolytic viruses have the capacity to selectively kill infected tumor cells and trigger protective immunity. As such, oncolytic virotherapy has become a promising immunotherapy strategy against cancer. A variety of viruses from different families have been proven to have oncolytic potential. Senecavirus A (SVA) was the first picornavirus to be tested in humans for its oncolytic potential and was shown to penetrate solid tumors through the vascular system. SVA displays several properties that make it a suitable model, such as its inability to integrate into human genome DNA and the absence of any viral-encoded oncogenes. In addition, genetic engineering of SVA based on the manipulation of infectious clones facilitates the development of recombinant viruses with improved therapeutic indexes to satisfy the criteria of safety and efficacy regulations. This review summarizes the current knowledge and strategies of genetic engineering for SVA, and addresses the current challenges and future directions of SVA as an oncolytic agent.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Edited by: Mihnea Bostina, University of Otago, New Zealand
Reviewed by: Bryan E. Strauss, Universidade de São Paulo, Brazil; Akbar Nawab, University of Florida, United States
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Oncology
These authors have contributed equally to this work and share first authorship
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2022.839536